nach oben

Breast Cancer

Erschienen in:

19.10.2018 | Original Article

Identification of genes associated with survival of breast cancer patients

verfasst von: Min Liu, Siying Zhou, Jinyan Wang, Qian Zhang, Sujin Yang, Jifeng Feng, Bin Xu, Shanliang Zhong

Erschienen in: Breast Cancer | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

We aimed to investigate the potential of microRNA expression profiles to predict survival in breast cancer.

Methods

MicroRNA and mRNA expression data of breast cancer were downloaded from The Cancer Genome Atlas. LASSO regression was used to identify microRNAs signature predicting survival of breast cancer patients. Transfection experiment was conducted to explore the influence of microRNAs on their potential targets.

Results

We identified 56 differentially expressed microRNAs in breast cancer tissues compared to adjacent normal tissues. 10 microRNAs with non-zero coefficient were selected from the 56 microRNAs using LASSO Cox regression. After predicting the targets for the 10 microRNAs, we further obtained 155 targets that were associated with overall survival of breast cancer patients. Spearman’s correlation analysis found that the expression of SCUBE2, SCRN3, YTHDF3, ITFG1, ITPRIPL2, and JAK1 was an inversely correlated with their microRNAs. Transfection experiment showed that YTHDF3 was down-regulated in cells transfected with miR-106b-5p mimics compared with those transfected with negative control of mimics (fold change 4.21; P < 0.01).

Conclusions

In conclusion, we identified a 10-miRNA signature associated with prognosis of breast cancer patients. The expression of YTHDF3 was down-regulated by miR-106b-5p.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; 67:7–30CrossRefPubMed

Esbah O, Oksuzoglu B. Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer. Indian J Med Res. 2017;146:563–71.PubMedPubMedCentral

Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol. 2018;52:56–73.CrossRefPubMed

He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522–31.CrossRefPubMed

Mandujano-Tinoco EA, Garcia-Venzor A, Melendez-Zajgla J, Maldonado V. New emerging roles of microRNAs in breast cancer. Breast Cancer Res Treat. 2018;171:247–59CrossRefPubMed

Teoh SL, Das S. The role of MicroRNAs in diagnosis, prognosis, metastasis and resistant cases in breast cancer. Curr Pharm Des. 2017;23:1845–59.CrossRefPubMed

Tang Y, Zhou X, Ji J, Chen L, Cao J, Luo J, et al. High expression levels of miR-21 and miR-210 predict unfavorable survival in breast cancer: a systemic review and meta-analysis. Int J Biol Mark. 2015;30:e347-58.

Kim SY, Kawaguchi T, Yan L, Young J, Qi Q, Takabe K. Clinical relevance of microRNA expressions in breast cancer validated using The Cancer Genome Atlas (TCGA). Ann Surg Oncol. 2017;24:2943–9.CrossRefPubMedPubMedCentral

Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Ser B (Methodol). 1996;58:267–88.

10.

Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19:A68–77.

11.

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.CrossRefPubMedPubMedCentral

12.

Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:279–84.CrossRefPubMed

13.

Alencar AJ, Malumbres R, Kozloski GA, Advani R, Talreja N, Chinichian S, et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res. 2011;17:4125–35.CrossRefPubMedPubMedCentral

14.

Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:e05005CrossRefPubMedCentral

15.

Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43:D146-52.PubMed

16.

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504.CrossRefPubMedPubMedCentral

17.

Zhong S, Wang J, Hou J, Zhang Q, Xu H, Hu J, et al. Circular RNA hsa_circ_0000993 inhibits metastasis of gastric cancer cells. Epigenomics. 2018;10:1301–13.CrossRefPubMed

18.

Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol. 2013;14:1295–306.CrossRefPubMed

19.

Hayes J, Thygesen H, Tumilson C, Droop A, Boissinot M, Hughes TA, et al. Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. Mol Oncol. 2015;9:704–14.CrossRefPubMed

20.

Feng YH, Tsao CJ. Emerging role of microRNA-21 in cancer. Biomed Rep. 2016;5:395–402.CrossRefPubMedPubMedCentral

21.

Barbano R, Pasculli B, Rendina M, Fontana A, Fusilli C, Copetti M, et al. Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients. Sci Rep. 2017;7:45283.CrossRefPubMedPubMedCentral

22.

Jiang CF, Shi ZM, Li DM, Qian YC, Ren Y, Bai XM, et al. Estrogen-induced miR-196a elevation promotes tumor growth and metastasis via targeting SPRED1 in breast cancer. Mol Cancer. 2018;17:83.CrossRefPubMedPubMedCentral

23.

Yang Z, Han Y, Cheng K, Zhang G, Wang X. miR-99a directly targets the mTOR signalling pathway in breast cancer side population cells. Cell Prolif. 2014;47:587–95.CrossRefPubMedPubMedCentral

24.

Hu Y, Zhu Q, Tang L. MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression. PLoS One. 2014;9:e92099.CrossRefPubMedPubMedCentral

25.

Ni X, Xia T, Zhao Y, Zhou W, Wu N, Liu X, et al. Downregulation of miR-106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2. Cancer Sci. 2014;105:18–25.CrossRefPubMed

26.

Lin YC, Chen CC, Cheng CJ, Yang RB. Domain and functional analysis of a novel breast tumor suppressor protein, SCUBE2. J Biol Chem. 2011;286:27039–47.CrossRefPubMedPubMedCentral

27.

Lin YC, Lee YC, Li LH, Cheng CJ, Yang RB. Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition. J Cell Sci. 2014;127:85–100.CrossRefPubMed

28.

Cheng CJ, Lin YC, Tsai MT, Chen CS, Hsieh MC, Chen CL, et al. SCUBE2 suppresses breast tumor cell proliferation and confers a favorable prognosis in invasive breast cancer. Cancer Res. 2009;69:3634–41.CrossRefPubMed

29.

Fan W, Xie J, Xia J, Zhang Y, Yang M, Wang H, et al. RUVBL1-ITFG1 interaction is required for collective invasion in breast cancer. Biochim Biophys Acta. 2017;1861:1788–800.CrossRef

30.

Quintas-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res. 2013;19:1933–40.CrossRefPubMedPubMedCentral

31.

Lee HJ, Seo NJ, Jeong SJ, Park Y, Jung DB, Koh W, et al. Oral administration of penta-O-galloyl-beta-d-glucose suppresses triple-negative breast cancer xenograft growth and metastasis in strong association with JAK1-STAT3 inhibition. Carcinogenesis. 2011;32:804–11.CrossRefPubMedPubMedCentral

32.

Kaushik N, Kim MJ, Kim RK, Kumar Kaushik N, Seong KM, Nam SY, et al. Low-dose radiation decreases tumor progression via the inhibition of the JAK1/STAT3 signaling axis in breast cancer cell lines. Sci Rep. 2017;7:43361.CrossRefPubMedPubMedCentral

Titel: Identification of genes associated with survival of breast cancer patients
verfasst von: Min Liu
Siying Zhou
Jinyan Wang
Qian Zhang
Sujin Yang
Jifeng Feng
Bin Xu
Shanliang Zhong
Publikationsdatum: 19.10.2018
Verlag: Springer Japan
Erschienen in: Breast Cancer / Ausgabe 3/2019
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-018-0926-9

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Identification of genes associated with survival of breast cancer patients

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Invasive breast cancers in adolescent and young adult women show more aggressive immunohistochemical and clinical features than those in women aged 40–44 years

Can quantitative evaluation of mammographic breast density, “volumetric measurement”, predict the masking risk with dense breast tissue? Investigation by comparison with subjective visual estimation by Japanese radiologists

Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil

OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database

Hypofractionated whole breast radiotherapy with or without hypofractionated boost in early stage breast cancer patients: a mono-institutional analysis of skin and subcutaneous toxicity

Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie